Publications by authors named "Gary Piazza"

Claim this Profile
E
Exploring dual inhibitors Carbonic Anhydrases and Phosphodiesterase 5 as potential agents for treatment Alzheimer's disease.
Alessia Costa, Gustavo Provensi, Costanza Titi, Manuela Leri, Monica Bucciantini, Gary A Piazza

Eur J Med Chem· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis.
Md Ibrahim, Gary A Piazza, Fakhrul Ahsan

Trends Pharmacol Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and Characterization of Novel Pan-RAS Inhibitor Loaded Ultraflexible Liposomes for the Topical Prevention or Treatment of Skin Melanoma.
Shivani A Dave, Adam B Keeton, Gary A Piazza, Anthony J Di Pasqua

Pharm Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Disulfiram-Loaded Metal-Organic Nanoparticles Inhibit Tumor Growth and Induce Immunogenic Cell Death of Triple-Negative Breast Cancer Cells.
Chung-Hui Huang, Xuejia Kang, Lang Zhou, Junwei Wang, Shuai Wu, Gary A Piazza

Pharmaceutics· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: RAS inhibitor therapy of cancer.
Donald J Buchsbaum, Nicolas N Nassar, Gary A Piazza

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.
Daniela D De Nobrega, Logan C Eiler, Parmanand Ahirwar, Sonika Nallapu, Urvi P Rawal, Gary A Piazza

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic nucleotide phosphodiesterases as drug targets.
Michy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, Claire Lugnier, Christian Hesslinger, Gary A Piazza

Pharmacol Rev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.
Sara Sigler, Mohammad Abdel-Halim, Reem K Fathalla, Luciana Madeira Da Silva, Adam B Keeton, Gary A Piazza

Anticancer Agents Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Jeremy B Foote, Tyler E Mattox, Adam B Keeton, Xi Chen, Forrest T Smith, Gary A Piazza

Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models.
Daniela De Nobrega, Logan C Eiler, Parmanand Ahirwar, Urvi P Rawal, Chelsea L Crawford, Gary A Piazza

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L Carstens, Jeremy B Foote, Gary A Piazza

Mol Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel phosphodiesterase 5 inhibitor, RF26, improves memory impairment and ameliorates tau aggregation and neuroinflammation in the P301S tauopathy mouse model of Alzheimer's disease.
Sara El-Desouky, Mohammad Abdel-Halim, Reem K Fathalla, Ashraf H Abadi, Gary A Piazza

Exp Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Jeremy B Foote, Tyler E Mattox, Adam B Keeton, Xi Chen, Forrest Smith, Gary A Piazza

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma.
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L Carstens, Jeremy B Foote, Gary A Piazza

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of KRAS inhibitors for colorectal cancer.
Gary A Piazza, Preethi Chandrasekaran, Yulia Y Maxuitenko, Karim I Budhwani

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents.
Noha Mostafa, Po-Jen Chen, Sarah S Darwish, Yu-Chieh Su, Ming-Hua Shiao, Gary A Piazza

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenyl-2-aminoethyl selenide ameliorates hippocampal long-term potentiation and cognitive deficits following doxorubicin treatment.
Ahmad H Alhowail, Matthew Eggert, Jenna Bloemer, Priyanka D Pinky, Lauren Woodie, Gary Piazza

PLoS One· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats.
Heather N Tinsley, Bini Mathew, Xi Chen, Yulia Y Maxuitenko, Nan Li, Gary A Piazza

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer.
Rebecca M Borneman, Elaine Gavin, Alla Musiyenko, Wito Richter, Kevin J Lee, Gary A Piazza

J Ovarian Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Targeting the Wnt/β-catenin signaling pathway in cancer.
Simone Patergnani, Donald J Buchsbaum, Gary A Piazza

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.
Nada S Aboelella, Caitlin Brandle, Ogacheko Okoko, Md Yeashin Gazi, Zhi-Chun Ding, Gary A Piazza

J Immunother Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel sulindac derivative protects against oxidative damage by a cyclooxygenase-independent mechanism.
Shailaja Kesaraju Allani, Ramanjaneyulu Rayala, Oscar Rivera, Howard M Prentice, Xi Chen, Gary A Piazza

J Pharmacol Exp Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Alexander B Coley, Antonio Ward, Adam B Keeton, Xi Chen, Yulia Maxuitenko, Gary A Piazza

Adv Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preface.
John P O'Bryan, Gary A Piazza

Adv Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The path to the clinic: a comprehensive review on direct KRAS inhibitors.
Albert K Kwan, Gary A Piazza, Adam B Keeton, Caio A Leite

J Exp Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis